Mirtazapine Eg

Mirtazapine, the active ingredient in Mirtazapine Eg, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral formulation for oral use. It is prescribed for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapine Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts on noradrenergic and serotonergic pathways to alleviate depressive conditions.

Major depressive disorder: reduces depressive symptoms and improves mood in adults. Depressive episodes in bipolar disorder: may be used as adjunct therapy under specialist supervision. Anxiety associated with depression: can help improve sleep and lessen anxiety symptoms.

Mirtazapine is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Suicidal thoughts or behavior - Serotonin syndrome when combined with other serotonergic agents - Severe hypersensitivity reactions (rash, angioedema) - Hepatic dysfunction or jaundice - Unexplained bleeding or bruising

Before initiating therapy, clinicians should consider several safety aspects. - Hepatic function: assess liver enzymes in patients with hepatic impairment. - Mood monitoring: watch for worsening depression or emergence of suicidal ideation. - Elderly patients: start at low dose and monitor for excessive sedation. - Concomitant CNS depressants: avoid additive sedation and respiratory depression. - Discontinuation: taper gradually to reduce risk of withdrawal symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis or serotonin syndrome. - Other serotonergic agents (SSRIs, SNRIs, tramadol): increased risk of serotonin syndrome. - CNS depressants (benzodiazepines, alcohol): enhanced sedation and respiratory depression. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): may raise mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: additive hypotensive effect. - Anticholinergic medications: heightened anticholinergic burden. - NSAIDs or anticoagulants: potential for increased gastrointestinal bleeding.